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Abstract
Background: Channeling occurs when a medication and its potential comparators are selectively prescribed based on
differences in underlying patient characteristics. Drug safety advisories can provide new information regarding the relative
safety or effectiveness of a drug product which might increase selective prescribing. In particular, when reported adverse
effects vary among drugs within a therapeutic class, clinicians may channel patients toward or away from a drug based on
the patient’s underlying risk for an adverse outcome. If channeling is not identified and appropriately managed it might
lead to confounding in observational comparative effectiveness studies.
Objective: To demonstrate channeling among new users of second generation antipsychotics following a Food and Drug
Administration safety advisory and to evaluate the impact of channeling on cardiovascular risk estimates over time.
Data Source: Florida Medicaid data from 2001–2006.
Study Design: Retrospective cohort of adults initiating second generation antipsychotics. We used propensity scores to
match olanzapine initiators with other second generation antipsychotic initiators. To evaluate channeling away from
olanzapine following an FDA safety advisory, we estimated calendar time-specific propensity scores. We compare the
performance of these calendar time-specific propensity scores with conventionally-estimated propensity scores on
estimates of cardiovascular risk.
Principal Findings: Increased channeling away from olanzapine was evident for some, but not all, cardiovascular risk factors
and corresponded with the timing of the FDA advisory. Covariate balance was optimized within period and across all
periods when using the calendar time-specific propensity score. Hazard ratio estimates for cardiovascular outcomes did not
differ across models (Conventional PS: 0.97, 95%CI: 0.81–3.18 versus calendar time-specific PS: 0.93, 95%CI: 0.77–3.04).
Conclusions: Changes in channeling over time was evident for several covariates but had limited impact on cardiovascular
risk estimates, possibly due to unmeasured confounding. Although calendar time-specific propensity scores appear to
improve covariate balance, the impact on comparative effectiveness results is limited in this setting.
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Background
Comparative effectiveness research (CER) aims to evaluate the
relative benefit or harms of treatment alternatives in patients who
are representative of those treated in real-world practice [1], as
opposed to the highly selected groups studied in randomized
controlled trials. Observational studies of administrative claims are
increasingly used for CER of pharmaceutical products. These
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studies need to address several important sources of bias, including
confounding due to changes in the clinical use of treatments over
time (i.e., channeling bias) [2]. Channeling occurs when users of a
medication and its potential comparators are selectively prescribed
a particular agent based on differences in underlying patient
characteristics [3]. If these characteristics also affect the risk for the
outcome of interest, channeling will lead to confounding.
The impact of calendar time-specific channeling is a particularly
important consideration when assessing the comparative safety for
drugs within a medication class targeted by a Food and Drug
Administration (FDA) safety advisory. In such cases, when
reported adverse effects vary among drugs within a therapeutic
class, clinicians may respond by channeling patients toward or
away from a particular treatment alternative based on the patient’s
underlying risk for an adverse outcome.
One way to address calendar time-specific channeling is
through the use of calendar time-specific propensity scores [4]
which estimate the probability of receiving treatment within
carefully defined study time periods anchored around changes in
policy or new safety or effectiveness information. This propensity
score can also provide insight into changes in channeling over time
and may provide better confounding control for treatment effect
estimates.
Clinical Context
Second generation antipsychotics (SGAs) are effective medica-
tions for the treatment of psychosis, but also have been associated
with metabolic adverse effects that increase the risks for
cardiovascular morbidity and mortality with long term use [5].
In late 2003, the FDA issued a class-wide advisory regarding
increased risks for metabolic adverse effects for patients using
second generation antipsychotics [6]. Shortly after the class-wide
warning was issued, members of the American Diabetes Associ-
ation, the American Psychiatric Association, the American
Association of Clinical Endocrinologists and the North American
Association for the Study of Obesity developed a professional
society consensus statement, identifying antipsychotic agents as
being of higher or lower metabolic risk based on evidence
available at that time [7]. This statement implicated clozapine and
olanzapine as the agents with the highest known metabolic risk,
with each of the other agents identified as being of either moderate
(quetiapine or risperidone) or low/unknown (aripiprazole or
ziprasidone) risk.
Previous studies identified large declines in olanzapine use
among Medicaid enrollees following the FDA advisory and
consensus statement publication [8–10]. Additional declines in
olanzapine use have been documented in Florida during the years
following the advisory, as Florida Medicaid temporarily imple-
mented a prior authorization policy to restrict access to this
product in July of 2005 [11]. It is unclear whether these observed
decreases in olanzapine use are due to reductions in olanzapine
use primarily among patients at higher risk for metabolic adverse
events, or if decreases in olanzapine use were non-selective. If the
former is true, channeling of patients at higher risk for adverse
metabolic-related outcomes away from olanzapine could result in
biased estimates of the comparative safety of second generation
antipsychotic agents, particularly as related to adverse metabolic
or cardiovascular related outcomes.
The objectives of this study are to evaluate (1) changes in
channeling of patients away from olanzapine over time; (2)
whether covariate balance is improved by matching within
calendar time-specific strata; and (3) whether use of calendar
time-specific propensity scores results in different cardiovascular
risk estimates among second generation antipsychotic users as
compared with unadjusted and traditional propensity score
matched analyses.
Study Data and Methods
Data Source
We used inpatient, outpatient and pharmacy claims from the
Florida Medicaid program from 2000–2006 for this analysis. This
data source contains inpatient, outpatient and prescription drug
utilization data for all paid claims for Florida’s fee-for-service
Medicaid enrollees. Florida’s Medicaid program is the fourth
largest in the country and represents an ethnically and racially
diverse population [12,13]. Furthermore, Medicaid insures a large
proportion of patients with severe mental illness and paid for the
majority of antipsychotic prescriptions in the US during this
period [13,14].
Study Time Periods
For the calendar time-specific propensity score, we measured
incident SGA use during three distinct time segments (January
2001–December 2002; January 2003–December 2003; January
2004–December 2005) that corresponded to relevant publications,
media reports, and FDA regulatory activities (See Table S1 for
details) [15–21].
Study Design and Cohort Identification
We created a retrospective cohort of new second generation
antipsychotic users for our analysis. We selected adults aged 18–64
who were enrolled in Florida’s fee-for-service Medicaid program.
Enrollees were required to have a new SGA prescription fill
between January 1, 2001 and December 31, 2005 and at least
6 months of continuous Medicaid enrollment prior to their index
prescription fill date (N = 37,130). SGAs included: olanzapine,
quetiapine, risperidone, ziprasidone, and aripiprazole. Clozapine
was excluded due to its infrequent use (,1% of SGA fills). From
this sample, we excluded individuals with codes for coronary
artery disease (acute myocardial infarction, coronary artery
revascularization, angina and chronic ischemic heart disease)
during the 6 months prior to drug initiation (N = 2,370). Finally,
we excluded enrollees who did not fill a second prescription for
their index second generation antipsychotic medication within 91
days or those who experienced an outcome of interest prior to
their second fill (N = 14,134). This resulted in a final sample of
20,626 Medicaid enrollees.
Follow Up
We followed these second generation antipsychotic initiators
from their second prescription fill date until they experienced a
cardiovascular outcome of interest, a gap in their Medicaid
enrollment of over 2 months or until December 31, 2006.
Enrollees who experienced a change in therapy (switching,
augmenting or discontinuing their index prescription (see
Table S2 for coding details)) were followed for up to 6 months
after their treatment change to identify relevant cardiovascular
outcomes allowing for a 6 months carry-over effect.
Dependent Variable
The primary outcome was coronary artery disease. We defined
coronary artery disease as acute myocardial infarction, coronary
artery revascularization (either percutaneous coronary interven-
tion or coronary artery bypass grafting), angina or chronic
ischemic heart disease (see Table S2 for coding details).
Channeling Bias and Comparative Effectiveness
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Table 1. Baseline Characteristics by Sample: 2001–2005.














Age at Index Fill Date – Means (SD) 42.3 (12.2) 41.8 (12.6) 42.2 (12.2) 42.0 (12.5) 42.1 (12.2) 42.2 (12.5)
18–29 17.9 19.9 18.3 19.1 18.3 18.6
30–39 21.5 21.2 21.4 21.6 21.5 21.9
40–49 30.1 28.6 30.9 29.0 30.0 28.3
50–64 30.5 30.3 30.2 30.3 30.2 31.2
Sex
Female 57.5 62.1 58.1 58.1 58.0 58.1
Race
White 46.2 51.7 47.5 47.5 47.9 47.9
Black 17.1 18.5 17.6 17.8 17.7 17.9
Hispanic 11.1 8.1 9.8 9.7 9.5 9.4
Other/Unknown 25.6 21.7 25.1 25.0 25.0 24.9
Medicaid Eligibility Category
Supplemental Security Income 65.4 64.8 65.9 65.8 66.1 66.1
Prior Health Services Utilization – Mean (SD)
Number of Outpatient Visits in Prior 6 Months 16.1 (21.2) 14.6 (18.4) 14.5 (18.5) 14.8 (18.7) 14.6 (18.5) 14.7 (18.9)
Number of Inpatient Visits in Prior 6 Months 1.8 (3.2) 2.0 (3.4) 1.8 (3.2) 1.8 (3.0) 1.8 (3.1) 1.8 (3.2)
Metabolic and Cardiovascular Risk Factors
Diabetes 8.5 11.5 8.7 8.9 8.7 8.8
Hyperlipidemia 9.3 9.6 9.0 9.2 8.8 8.4
Hypertension 23.9 27.4 24.0 23.4 23.9 23.9
Obesity 1.2 2.1 1.2 1.1 1.2 1.2
Peripheral Vascular Disease 2.2 1.6 1.9 1.7 1.6 1.8
Cerebrovascular Disease 3.0 2.9 2.9 2.8 3.0 2.9













Heart Failure 1.4 1.9 1.4 1.5 1.4 1.5
Pulmonary Disease 11.8 9.2 10.8 10.8 11.2 11.2
Thrombotic Disease 4.8 3.9 4.4 4.4 4.3 4.5
Other Previous Treatment
Aspirin 2.7 3.1 2.6 2.6 2.7 2.6
Non-Steroidal Anti-Inflammatory Agents 14.3 13.2 13.4 13.2 13.4 13.1
Antiplatelet Agents 2.1 2.4 2.1 2.0 2.0 2.1
Cox-2 Inhibitors 13.7 10.9 13.0 12.9 13.0 12.7
Mental Health Diagnoses
Schizophrenia 20.1 19.4 20.4 20.8 20.5 20.4
Bipolar Disorder 10.9 10.5 11.1 10.5 11.0 11.0
Psychosis 2.9 3.8 3.0 2.9 3.1 3.1
Mental Health-Related Comorbidities
Dementia 0.5 0.8 0.4 0.5 0.5 0.5
Major Depressive Disorder 22.6 27.8 23.2 23.3 23.2 23.8
Anxiety Disorder 10.1 11.8 10.3 10.6 10.3 10.3
Substance Abuse 7.8 8.0 7.9 7.8 7.9 7.8
Prior Psychiatric Treatment
Inpatient Mental Health Treatment 21.0 22.8 21.4 21.5 21.4 21.7
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Covariates
Variables potentially associated with both second generation
antipsychotic treatment selection and coronary artery disease, or
coronary artery disease alone, were included in the propensity
score model. These include: patient age (in years), sex, race (white,
black, Hispanic or other), Medicaid eligibility (Supplemental
Security Income or other), Medicaid region (categorized as 1–11
based on pre-defined regions within the Florida Medicaid
program), prior health services utilization (number of inpatient
visits, number of outpatient visits, presence of inpatient services for
mental health treatment, receipt of care from a psychiatrist),
metabolic or cardiovascular related comorbidities (diabetes,
hyperlipidemia, hypertension, obesity, peripheral vascular disease,
cerebrovascular disease, cardiac arrhythmias, heart failure),
mental health related conditions (schizophrenia, bipolar disorder,
psychosis, dementia, substance abuse, major depressive disorder,
anxiety disorder), prior medication use indicating or increasing
potential for cardiovascular risk (cox-2 inhibitors, NSAIDs,
aspirin, antiplatelet medications) and measures of medical
comorbidity (using the conditions identified in the Charlson
comorbidity index separately) [22]. Variables were dichotomized
unless otherwise indicated.
Analytic Methods–Propensity Score Estimation and
Channeling Identification
Propensity scores were estimated using logistic regression by
modeling the predicted probability of receiving olanzapine as a
function of the covariates measured in the 6 months prior to the
index prescription fill date. We created propensity score-matched
cohorts in which patients initiating treatment with olanzapine
were matched 1:1 to those initiating any other second generation
antipsychotic medication. To create the propensity score matched
cohorts we used a 5R1 propensity score digit matching algorithm
[23]. In all, there were 47 parameters estimated in the PS model,
providing approximately 26 events per predictor using the revised
sample/time periods.
To evaluate changes in channeling away from olanzapine over
time we estimated propensity scores separately in each pre-defined
time period and constructed calendar time-specific propensity
score-matched cohorts within each time period. We then
combined the resulting datasets for the matched-pairs analysis.
To evaluate the relative performance of the calendar time-specific
propensity score, we also estimated a conventional propensity
score (using all available data from January 2001–December
2005), while controlling for the year of initiation using dummy
variables. As with the calendar time-specific propensity score, we
used the same pre-treatment covariates in the conventional
propensity score model and we utilized the 5R1 digit propensity
score matching algorithm to generate matched pairs for analysis.
For the conventional propensity score model, matches were made
across all periods, rather than restricting to within-period matches.
Adjusted odds ratios from each of the propensity score
estimation models were estimated overall and within each
calendar time period to identify channeling of patients away from
olanzapine over time. Channeling was investigated for covariates
that were strong predictors of coronary artery disease and for
conditions specifically identified in the metabolic risk advisory and
consensus statement. Changes in channeling by covariate over
time were assessed using the Cochran-Armitage test for trend. We
calculated the absolute standardized mean differences to evaluate
between-group covariate balance across key covariates overall and
within period to assess the performance of each propensity score
matching method [24].
Analytic Methods–Estimating Model-Specific Changes in
Cardiovascular Outcomes
We estimated overall and period-specific hazard ratios for
cardiovascular outcomes for patients using olanzapine versus those
using other second generation antipsychotics using Cox Propor-
tional Hazard Models. We compare estimates from the unadjusted
model with estimates from the conventional propensity score-
matched and calendar time-specific propensity score-matched
cohorts. Because the propensity score matching techniques are
used to balance characteristics of our treatment and control groups
we do not include additional covariates in these models.
Sensitivity Analyses
In sensitivity analyses we reduced the post-censored observation
time for enrollees who experienced a change in therapy (switching,
augmenting or discontinuing their index prescription) from
6 months to 3 months to determine the extent to which the
longer timeframe might bias our estimates of drug-related
cardiovascular outcomes. Additionally, as sensitivity analysis for
our primary ‘‘as treated’’ analysis, we used an intent-to-treat
approach in which individuals were assumed to continue on their
index prescription fill until they experienced a cardiovascular
outcome of interest, a gap in their Medicaid enrollment of over
2 months or until December 31, 2006.
Table 1. Cont.













Visits to a Psychiatrist 46.2 51.4 47.3 46.6 47.3 47.0
Other Medical Comorbidities
1+ 19.4 17.5 18.6 18.5 18.5 18.5
Incident Prescription Period
Period 1 (Jan 2001 – Dec 2002) 57.8 38.0 56.6 56.7 56.3 56.3
Period 2 (Jan 2003 – Dec 2003) 24.7 22.2 25.2 25.0 25.4 25.4
Period 3 (Jan 2004 – Dec 2005) 17.6 39.8 18.2 18.3 18.3 18.3
doi:10.1371/journal.pone.0063973.t001
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Results
Cohort Characteristics
Before matching there were 7,082 new users of olanzapine and
13,544 new users of other second generation antipsychotic agents
included in the sample (Table 1). Of those, 96% of olanzapine
users were successfully matched in both the traditional propensity
score model and the calendar time-specific model. In the calendar
time-specific model, match percentages were 93.4% in period 1,
97.9% in period 2 and 99.8% in period 3. As compared with
individuals initiating olanzapine, before matching, those initiating
other second generation antipsychotic agents over the study period
had less frequent health services utilization (average of 14.6 versus
16.1 outpatient visits in the prior 6 months), and were more likely
to have diabetes (11.5% versus 8.5%) and hypertension (27.4%
versus 23.9%) and less likely to have pulmonary disease (9.2%
versus 11.8%).
Table 2. Channeling within and Across Periods for the Top Predictors of Coronary Artery Disease.
Patient Characteristics Period Odds Ratio 95% CI P-value for Trend
Age Over 50 Years 2001-2005 1.07 1.00-1.16
Period 1 1.01 0.91-1.12 0.27
Period 2 1.19 1.03-1.38
Period 3 1.07 0.92-1.24
White Race 2001-2005 0.78 0.73-0.83
Period 1 0.75 0.69-0.82 0.05
Period 2 0.72 0.64-0.82
Period 3 0.90 0.79-1.03
Prior Diabetes 2001-2005 0.72 0.65-0.81
Period 1 0.70 0.60-0.82 0.36
Period 2 0.73 0.59-0.91
Period 3 0.79 0.63-0.98
Prior Hyperlipidemia 2001-2005 1.17 1.05-1.30
Period 1 1.28 1.08-1.50 0.02
Period 2 1.05 0.84-1.31
Period 3 0.97 0.79-1.19
Prior Hypertension 2001-2005 0.88 0.82-0.95
Period 1 0.95 0.85-1.06 0.05
Period 2 0.82 0.70-0.95
Period 3 0.81 0.69-0.95
Prior Heart Failure 2001-2005 0.73 0.56-0.94
Period 1 0.62 0.43-0.88 0.15
Period 2 0.82 0.48-1.41
Period 3 0.94 0.57-1.54
Prior Peripheral Vascular Disease 2001-2005 1.32 1.05-1.66
Period 1 1.56 1.14-2.15 0.11
Period 2 1.12 0.68-1.82
Period 3 1.10 0.68-1.78
Prior Pulmonary Disease 2001-2005 1.44 1.30-1.60
Period 1 1.28 1.11-1.48 0.08
Period 2 1.68 1.36-2.07
Period 3 1.59 1.29-1.95
*P-value is for the interaction between period and the named covariate.
doi:10.1371/journal.pone.0063973.t002
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Channeling of Patients Away from Olanzapine
We evaluated channeling by period for the top predictors of
coronary artery disease in our sample (Table 2). Channeling was
not evident for most predictors of coronary artery disease when
comparing the odds ratios generated in period 1 to those
generated in each subsequent period. However, for patients with
prior diagnoses of hyperlipidemia and hypertension we see some
evidence that those patients were less likely to receive olanzapine
over time (p-value for trend: 0.02 and 0.05, respectively).
Impact of Estimation Strategy on Covariate Balance
We used the average standardized mean difference to assess
within- and across-period covariate balance for the top predictors
of coronary artery disease (Table 3). Covariate balance was









Mean Age 2001-2005 0.135 0.054 0.021
Period 1 0.171 0.084 0.008
Period 2 0.352 0.112 0.078
Period 3 0.039 0.118 0.029
White Race 2001-2005 0.110 0.000 0.000
Period 1 0.119 0.021 0.010
Period 2 0.119 0.012 0.012
Period 3 0.001 0.079 0.014
Prior Diabetes 2001-2005 0.101 0.009 0.005
Period 1 0.085 0.004 0.005
Period 2 0.094 0.040 0.002
Period 3 0.086 0.021 0.008
Prior Hyperlipidemia 2001-2005 0.008 0.007 0.014
Period 1 0.065 0.026 0.011
Period 2 0.015 0.058 0.014
Period 3 0.024 0.028 0.023
Prior Hypertension 2001-2005 0.082 0.012 0.001
Period 1 0.011 0.034 0.001
Period 2 0.078 0.040 0.004
Period 3 0.072 0.021 0.013
Prior Heart Failure 2001-2005 0.039 0.003 0.008
Period 1 0.059 0.003 0.019
Period 2 0.021 0.009 0.005
Period 3 0.009 0.017 0.019
Prior Peripheral Vascular
Disease
2001-2005 0.040 0.014 0.015
Period 1 0.065 0.024 0.015
Period 2 0.022 0.006 0.009
Period 3 0.005 0.013 0.023
Prior Pulmonary Disease 2001-2005 0.086 0.003 0.000
Period 1 0.057 0.020 0.005
Period 2 0.116 0.003 0.020
Period 3 0.126 0.076 0.015
doi:10.1371/journal.pone.0063973.t003
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improved in both the conventional and calendar time-specific
propensity score matched cohorts as compared with the
unmatched cohort. Overall, the calendar time-specific propensity
score model produced smaller standardized differences than the
conventional propensity score for 23 of 32 comparisons. In the
remaining 9 comparisons, differences between the two models
were small (usually less than 0.02).
Impact of Estimation Strategy on Hazard Ratio Estimates
We estimated the hazard ratio for coronary artery disease
among individuals using olanzapine versus those using any other
second generation antipsychotic agent (Table 4). Models were
estimated for the entire study period (2001–2005) and separately
by period. In unadjusted models we observe a hazard ratio of 0.96
(95% CI: 0.82–3.05) for the full study period. These estimates were
unchanged in both the conventional propensity score matched
analysis and the calendar time-specific propensity score matched
analysis (HR: 0.97, 95%CI: 0.81–3.18, conventional PS; HR:
0.93, 95%CI: 0.77–3.04, CTS PS). Similarly, we found no
differences in hazard ratio estimates across any model or any
period.
Sensitivity Analyses
Results from sensitivity analyses reducing post-censored follow-
up time from 6 months to 3 months and utilizing an intent-to-
treat approach for classifying person-time of exposure were
similar to results obtained in the primary analysis (not shown).
Discussion
Researchers intending to use administrative or secondary data
sources for the purposes of comparative effectiveness and safety
studies should consider the important role that policies and
regulatory decisions play in shaping the use of treatments over
time. In prescription drug-related research, the characteristics of
populations receiving a particular treatment may vary over time
with new drug approvals, new entries into a class, and regulatory
warnings regarding emerging safety concerns. Here, we investigate
whether concerns about increased metabolic risk for olanzapine
shifted prescribing among second generation antipsychotic users.
We found some evidence of diagnosis-specific channeling of
patients at higher cardio-metabolic risk away from olanzapine
following an FDA advisory and subsequent consensus statement
that highlighted these risks. In particular, individuals with prior
hyperlipidemia and hypertension became less likely to receive
olanzapine over time. However, channeling was not evident for
other key risk factors, such as diabetes. Interestingly, in this sample
patients with diabetes were less likely to receive olanzapine than
other SGAs in each period, even those before the advisory. This
suggests that clinicians were selectively prescribing non-olanzapine
SGAs for patient with diabetes even before the advisory period.
Conventional propensity score models that control for time
provide an overall estimate of the effect of a predictor on the
likelihood of using a specific treatment but a ‘‘null’’ effect over a
period may represent a higher likelihood of receiving the drug at
one point and a lower likelihood of receiving the drug at another.
Estimates of the odds of receiving olanzapine among patients with
prior hyperlipidemia provide the best demonstration of this from
our sample. Here we see that the overall point estimate is 1.17 for
the study period, but period-to-period estimates range from 1.28 in
period 1 to 0.97 in period 3. Note that the overall estimate is
balanced on this measured covariate and would provide a valid
estimate over the full study period. However, once we condition
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at least some of the calendar time strata) covariate balance is no
longer achieved using the matched pairs identified in the
conventional model.
We had hypothesized that olanzapine use would increase the
risk for cardiovascular adverse events prior to the advisory, but
that this association would fade over time even with proper control
for measured confounders as individuals with higher baseline risk
not captured by measured covariates were moved away from
olanzapine. In our sample, estimates of the comparative effective-
ness of second generation antipsychotics on cardiovascular
outcomes did not appear to be influenced by estimation strategy.
The small number of outcome events and unmeasured confound-
ing appeared to influence our ability to detect any differences
between olanzapine and other SGAs for adverse cardiovascular
outcomes.
A key consideration when selecting a propensity scoring strategy
is how well the resulting propensity score matched groups are
balanced on measured characteristics. While we found only minor
differences in the covariate balance between propensity score
estimation strategies, we did find that within-period balance was
improved by using a calendar time-specific propensity scoring
model. While both matching strategies appeared to improve
covariate balance overall, investigators who are concerned with
investigating within-period differences would benefit from using a
calendar time-specific propensity score method. This method is
easy to implement and allows for within period comparisons
without resulting in ‘‘breaking’’ the matches created in a
conventional propensity score model. Additionally, the calendar
time-specific propensity score allows appropriate changes in
assignment of propensity for treatment receipt for each covariate
and forces matches to be made within the investigator-specified
time periods so that treatment and control groups are well
balanced over each period when changes in channeling may be
occurring.
Specific limitations include a lack of information on important
unmeasured risk factors for cardiovascular disease (e.g., smoking,
family history of cardiovascular disease) or poorly measured
cardiovascular risk factors (e.g., potential under-coding of diabetes,
hyperlipidemia and obesity) that may influence prescribing of
olanzapine. It is important to realize, however, that due to our
study design using an active comparator cohort, this only leads to
confounding bias if these cardiovascular risk factors also affect
channeling between olanzapine and other second generation
antipsychotics. While we observed some evidence for bias due to
unmeasured confounding, this does not reduce our ability to detect
and control for changes in measured channeling over time.
Second, the heterogeneous composition of our comparison group
may influence our ability to detect differences in channeling and/
or cardiovascular risk (e.g., including all non-olanzapine second
generation antipsychotic agents, which vary in metabolic risk).
Further, as a result of the drug safety advisory, olanzapine use
declined steadily over the study period. This reduced the sample
size available for later periods. Additionally, other factors may
have influenced the use of SGAs over our time period, including
drug promotion and drug approvals within the class. Regarding
the latter point, a low metabolic risk SGA (aripiprazole) was
approved during our study period and may have influenced our
estimates of channeling. Next, the best prediction model for
detecting channeling may not be the best model to control for
confounding, which is the primary goal of the PS model [25]. We
implemented the propensity score using matching to simplify the
presentation of our results. Propensity score matching allows us to
estimate the treatment effect in the treated (olanzapine users).
Other researchers may elect to use alternate propensity score
implementation strategies (e.g., weighting or stratification),
depending on the treatment effect of interest [26]. It will be
important for future studies to estimate the impact of these
different propensity scoring estimation and implementation
methods on both covariate balance and on health outcomes.
Conclusions
Although calendar time-specific propensity scores appear to
improve covariate balance, the impact on comparative effective-
ness results is limited in this setting. Future work is needed to
examine the utility of this method in observational comparative
effectiveness research. Researchers should consider using calendar
time-specific propensity scores to improve covariate balance and
to identify and potentially reduce channeling bias in studies where
prescription drug prescribing practices might have changed over
time and calendar time-specific channeling is suspected.
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